Scholarlink

<p>Pain is a&#xa0;common leading symptom in many rheumatic diseases. The World Health Organization differentiates nociceptive, neuropathic, and nociplastic pain. This distinction determines further diagnostic and therapeutic measures. Nociceptive pain arises following stimulation of peripheral nociceptors in degenerative syndromes and in systemic inflammatory diseases. For the latter group, immunosuppressants are available that target disease-specific molecules. Nonsteroidal anti-inflammatory drugs (NSAIDs) and physiotherapy, among other treatments, are recommended for degenerative syndromes. Disease-specific target molecules are not yet available. Neuropathic pain arises from injury to central or peripheral somatosensory neurons. Disease-specific target molecules are limited as therapeutic strategies. Nociplastic syndromes, as the third group, develop following changes in pain perception in the peripheral and central nervous systems. It is often associated with whole-body pain and psychological symptoms. Disease-specific target molecules for therapeutic intervention are also limited in this group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schmerzsyndrome in der Rheumatologie

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Matthias F. Seidel

摘要

Pain is a common leading symptom in many rheumatic diseases. The World Health Organization differentiates nociceptive, neuropathic, and nociplastic pain. This distinction determines further diagnostic and therapeutic measures. Nociceptive pain arises following stimulation of peripheral nociceptors in degenerative syndromes and in systemic inflammatory diseases. For the latter group, immunosuppressants are available that target disease-specific molecules. Nonsteroidal anti-inflammatory drugs (NSAIDs) and physiotherapy, among other treatments, are recommended for degenerative syndromes. Disease-specific target molecules are not yet available. Neuropathic pain arises from injury to central or peripheral somatosensory neurons. Disease-specific target molecules are limited as therapeutic strategies. Nociplastic syndromes, as the third group, develop following changes in pain perception in the peripheral and central nervous systems. It is often associated with whole-body pain and psychological symptoms. Disease-specific target molecules for therapeutic intervention are also limited in this group.